Form 8-K - Current report:
SEC Accession No. 0000950170-25-053523
Filing Date
2025-04-14
Accepted
2025-04-14 09:15:10
Documents
15
Period of Report
2025-04-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20250411.htm   iXBRL 8-K 86558
2 EX-3.1 tcrt-ex3_1.htm EX-3.1 161024
3 EX-10.1 tcrt-ex10_1.htm EX-10.1 161262
4 GRAPHIC img41163667_0.jpg GRAPHIC 59814
5 GRAPHIC img169896105_0.jpg GRAPHIC 15132
  Complete submission text file 0000950170-25-053523.txt   684872

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20250411.xsd EX-101.SCH 28389
18 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20250411_htm.xml XML 5069
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 25834350
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)